Cytos Biotechnology AG

EQS-Adhoc: Cytos Biotechnology Ltd. will be renamed Kuros Biosciences Ltd., constitutes its Board of Directors and appoints Executive Officers


EQS Group-Ad-hoc: Cytos Biotechnology AG / Key word(s): Mergers & Acquisitions
Cytos Biotechnology Ltd. will be renamed Kuros Biosciences Ltd., constitutes its
Board of Directors and appoints Executive Officers

08.01.2016 / 07:00
Release of an ad hoc announcement pursuant to Art. 53 KR.
The issuer is solely responsible for the content of this announcement.

--------------------------------------------------------------------------------
Cytos Biotechnology Ltd. will be renamed Kuros Biosciences Ltd., constitutes its
Board of Directors and appoints Executive Officers

Schlieren (Zurich), Switzerland, January 8, 2016 - Cytos Biotechnology Ltd
("Cytos" or the "Company" - to be renamed Kuros Biosciences Ltd.), announced
today that the Board of Directors has constituted itself with Dr. Christian Itin
stepping down as CEO but remaining as Chairman of the Board and Mr. Dominik
Ellenrieder being appointed as the Vice Chairman of the Board. Further, the
newly constituted Board elected Didier Cowling as Chief Executive Officer, Dr.
Alistair Irvine as Chief Business Officer, Dr. Jason Schense as Chief Technology
Officer and confirmed Harry Welten as the Chief Financial Officer. All
appointments are effective upon closing of the acquisition of Kuros Biosurgery
Holding AG which is expected to take place within the next few weeks.

"Yesterday, Cytos has received overwhelming support by our shareholders for the
acquisition of Kuros Biosurgery Ltd. With the closing of the transaction most
existing members of the Board will step down and new members of the Board of
Directors have been elected. I would like to thank the outgoing Board members
for their continued support and welcome the new members of the board and
executive management", commented Christian Itin, Chairman of Cytos. "We are
pleased that Harry Welten will continue as Chief Financial Officer and are
looking forward to forming Kuros Biosciences".

For further information, please contact:

Cytos Biotechnology Ltd
Harry Welten, MBA
Chief Financial Officer
Tel: +41 44 733 46 46
harry.welten@cytos.com

About Cytos Biotechnology Ltd

Cytos is a public biopharmaceutical company located in Schlieren (Zurich),
Switzerland. The Company is listed according to the Main Standard on the SIX
Swiss Exchange Ltd under the symbol CYTN.

Forward Looking Statements
This media release contains certain forward-looking statements that involve
risks and uncertainties that could cause actual results to be materially
different from historical results or from any future results expressed or
implied by such forward-looking statements. You are urged to consider statements
that include the words "will" or "expect" or the negative of those words or
other similar words to be uncertain and forward-looking. Factors that may cause
actual results to differ materially from any future results expressed or implied
by any forward-looking statements include scientific, business, economic and
financial factors, Against the background of these uncertainties, readers should
not rely on forward-looking statements. The Company assumes no responsibility
for updating forward-looking statements or adapting them to future events or
developments.

www.cytos.com


End of ad hoc announcement

+++++
Additional features:

Document:http://n.eqs.com/c/fncls.ssp?u=XGGVUXDFGF
Document title: Cytos_160108

--------------------------------------------------------------------------------
08.01.2016 News transmitted by EQS Schweiz AG. www.eqs.com - news archive:
http://switzerland.eqs.com/de/News

The issuer is responsible for the contents of the release.
--------------------------------------------------------------------------------

Language: English

Company:  Cytos Biotechnology AG

          Wagistr. 25

          8952  Schlieren

          Switzerland

Phone:    +41 44 733 4747

Fax:      +41 44 733 4740

E-mail:info@cytos.com

Internet: www.cytos.com

ISIN:     CH0011025217, CH0029060735

Valor:    -

Listed:   Regulated Unofficial Market in Berlin, Munich, Stuttgart; Open Market
in Frankfurt ; SIX


End of News EQS Group News Service
--------------------------------------------------------------------------------
427737  08.01.2016 
 

 


Das könnte Sie auch interessieren: